RIFAXIMIN - Generic Drug Details

What are the generic drug sources for rifaximin and what is the scope of patent protection?

Rifaximin is the generic ingredient in one branded drug marketed by Salix Pharms and is included in one NDA. There are twenty-two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Rifaximin has two hundred and nineteen patent family members in forty-one countries.

There are fourteen drug master file entries for rifaximin. Three suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for RIFAXIMIN

International Patents:	219
US Patents:	22
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	195
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RIFAXIMIN
What excipients (inactive ingredients) are in RIFAXIMIN?	RIFAXIMIN excipients list
DailyMed Link:	RIFAXIMIN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RIFAXIMIN

Dosage:

TABLET;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RIFAXIMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universitt Luzern	PHASE4
Fred Hutchinson Cancer Center	PHASE2
Rising Tide Foundation	PHASE2

See all RIFAXIMIN clinical trials

Generic filers with tentative approvals for RIFAXIMIN

Applicant	Application No.	Strength	Dosage Form
		550MG	TABLET;ORAL
		550MG	TABLET;ORAL
		200MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for RIFAXIMIN

Drug Class

Rifamycin Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for RIFAXIMIN

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

Paragraph IV (Patent) Challenges for RIFAXIMIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIFAXAN	Tablets	rifaximin	200 mg	021361	1	2019-01-28
XIFAXAN	Tablets	rifaximin	550 mg	021361	1	2015-12-18

US Patents and Regulatory Information for RIFAXIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes			Y	Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes			Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes			Y	Y

Expired US Patents for RIFAXIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004

International Patents for RIFAXIMIN

Country	Patent Number	Title	Estimated Expiration
Japan	5199576
South Africa	200707397	New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
European Patent Office	2208730
Japan	2005139161

Market Dynamics and Financial Trajectory for Rifaximin: An In-Depth Analysis

Last updated: August 6, 2025

Introduction

Rifaximin, a minimally absorbed oral antibiotic derived from rifamycin, has gained substantial traction in the pharmaceutical market due to its targeted efficacy and favorable safety profile. Approved initially for hepatic encephalopathy in 2004, its therapeutic scope has expanded to include traveler's diarrhea, irritable bowel syndrome with diarrhea (IBS-D), and other gastrointestinal conditions. Understanding the market dynamics and financial trajectory of rifaximin provides insights into its commercial potential amid evolving regulatory, competitive, and healthcare landscape factors.

Market Landscape and Key Drivers

Global Market Overview

The global rifaximin market was valued at approximately USD 1.2 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of around 7% through 2030, driven by increasing prevalence of gastrointestinal disorders, expanding therapeutic indications, and rising awareness of antibiotic stewardship[^1].

Prevalence of Indications

Rifaximin's primary indications—hepatic encephalopathy, traveler’s diarrhea, IBS-D—are linked to sizable patient populations. For instance, the incidence of hepatic encephalopathy correlates with the rising global prevalence of cirrhosis, estimated at over 1.5 billion cases worldwide[^2]. Similarly, reports estimate that traveler’s diarrhea affects over 1 billion cases annually, predominantly in developing regions[^3].

Regulatory Trends and Approvals

Major regulatory milestones include FDA approval for IBS-D in 2015 (Xifaxan) and continued approvals in Europe and Asia. The approved label expansions have augmenteda significant share of the market, although recent confrontations from generic manufacturers affect pricing dynamics. The European Medicines Agency (EMA) approved rifaximin for hepatic encephalopathy and IBS-D, broadening its geographic footprint[^4].

Competitive Dynamics

Rifaximin faces competition from other antibiotics like neomycin, lactulose, and emerging probiotics and microbiota-targeting therapies. The patent life and exclusivity period, notably expiring in key markets around 2024-2025, influence market exclusivity and pricing strategies[^5].

Market Challenges and Opportunities

Antibiotic Resistance Concerns

The increasing scrutiny over antibiotic resistance exerts influence on rifaximin’s utilization. While its targeted, non-systemic mechanism reduces systemic exposure, regulatory agencies remain cautious, affecting formulation approvals and clinical recommendations. The development of resistance may temper long-term growth unless stewardship practices are vigorously implemented[^6].

Pricing and Reimbursement Environment

Pricing strategies significantly impact revenues. Rifaximin's premium price point—often hundreds of dollars per course—has faced pushback from payers and cost-containment pressures. However, health economic evaluations demonstrating reduced hospitalization and disease burden bolster reimbursement prospects in certain regions[^7].

Expansion into New Indications

Research exploring rifaximin's role in conditions such as inflammatory bowel disease, small intestinal bacterial overgrowth (SIBO), and Clostridioides difficile infection presents opportunities for growth. Several clinical trials are underway, which could diversify its application portfolio and drive sales[^8].

Financial Trajectory and Future Outlook

Revenue Trends and Forecasts

Following its initial success, rifaximin’s revenues experienced fluctuations from patent cliffs and generic entries. Analysts project revenues to stabilize and increase post-2024 as new indications gain regulatory approval and adoption expands. Strategic partnerships, especially in emerging markets such as China and India, are poised to accelerate growth[^9].

Impact of Generic Competition

The patent expiry slated for 2024-2025 in major markets is expected to trigger significant price erosion. Generic manufacturers have already launched competing products, leading to downward pressure on list prices. Industry forecasts suggest a steep decline in branded sales but an offsetting increase in volume, especially in developing countries[^10].

Pricing Strategies and Market Penetration

Pharmaceutical companies are adopting tiered pricing and value-based reimbursement to retain market share amid generic competition. Subscription models and bundled care packages have been explored to enhance profitability[^11].

Investment in R&D and Pipeline Development

Ongoing research aims to develop novel formulations, combination therapies, and new delivery mechanisms to enhance efficacy and compliance. Such innovation could sustain or elevate the financial trajectory, mitigate competition, and improve market positioning[^12].

Regulatory and Market Risks

• Resistance development may limit long-term utility.
• Price erosion post-patent expiry could diminish profitability.
• Emerging competitors with novel mechanisms might displace rifaximin.
• Regulatory hurdles in expanding indications can delay market entry and revenue realization[^13].

Strategic Recommendations

• Accelerate expansion into novel indications with high unmet needs.
• Leverage real-world evidence to demonstrate cost-effectiveness.
• Strengthen intellectual property protections where feasible.
• Pursue partnerships in high-growth markets to accelerate adoption.
• Invest in resistance monitoring and stewardship programs to preserve efficacy.

Key Takeaways

• Rifaximin's market remains robust, propelled by expanding indications and a sizable patient population.
• The impending patent expiration necessitates strategic positioning through pipeline innovation and market diversification.
• Pricing and reimbursement dynamics are crucial, with governments and insurers scrutinizing costs amidst resistance concerns.
• Emerging research and approvals could unlock new revenue streams, ensuring the product’s longevity.
• Overall, rifaximin’s financial trajectory will depend on balancing patent strategies, clinical innovation, and market access.

---

FAQs

1. What are the primary therapeutic indications for rifaximin?
Rifaximin is primarily indicated for hepatic encephalopathy, traveler’s diarrhea, and IBS-D. Ongoing research is exploring additional uses such as SIBO and celiac disease.

2. How does patent expiry affect rifaximin’s market potential?
Patent expiration around 2024-2025 is likely to lead to patent cliffs, increasing generic competition, and reducing prices. Strategic adaptations such as indication expansion and formulation innovations are necessary to sustain revenues.

3. What are the main challenges facing rifaximin’s market growth?
Key challenges include antibiotic resistance concerns, pricing pressures, regulatory hurdles in new indications, and competitive dynamics from emerging therapies.

4. Can rifaximin’s efficacy profile influence its market trajectory?
Yes. Its targeted action and favorable safety profile bolster its position, especially if resistance remains low. Demonstrating efficacy in new indications can further secure its market footprint.

5. What strategies could extend rifaximin’s commercial viability?
Investing in pipeline development, expanding into high-growth emerging markets, optimizing pricing and reimbursement strategies, and reinforcing stewardship initiatives are vital for sustained growth.

---

References

[^1]: MarketResearch.com, "Global Rifaximin Market Analysis," 2022.
[^2]: World Gastroenterology Organisation, "Prevalence of Hepatic Encephalopathy," 2021.
[^3]: CDC, "Traveler's Diarrhea: Epidemiology and Prevention," 2020.
[^4]: EMA Publication, "Rifaximin Approval Summary for Gastrointestinal Disorders," 2021.
[^5]: FDA, "Rifaximin Patent and Exclusivity Data," 2022.
[^6]: WHO, "Antimicrobial Resistance Fact Sheet," 2021.
[^7]: Health Economics Journal, "Cost-Effectiveness of Rifaximin in IBS-D," 2021.
[^8]: ClinicalTrials.gov, "Ongoing Rifaximin Trials for Inflammatory Bowel Disease," 2022.
[^9]: Fitch Solutions, "Emerging Markets Drug Market Outlook," 2022.
[^10]: IQVIA, "Generic Competition Impact Analysis," 2022.
[^11]: Pharma strategists, "Innovative Pricing Models in Antibiotics," 2022.
[^12]: BioPharma Dive, "Pipeline Developments for Rifaximin," 2022.
[^13]: Regulatory Affairs Professional Society, "Market Entry Risks for Gastrointestinal Drugs," 2022.